NCT03715972View on ClinicalTrials.gov

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

CompletedOBSERVATIONAL
Enrollment

165

Participants

Timeline

Start Date

July 15, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
ThalassemiaSickle Cell DiseaseHealthy Controls
Interventions
DRUG

Hydroxyurea

info included in arm group

DRUG

Acetazolamide

Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.

Trial Locations (1)

90027

CHLA, Los Angeles

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

lead

Children's Hospital Los Angeles

OTHER

NCT03715972 - Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia | Biotech Hunter | Biotech Hunter